SOPHiA GENETICS was founded in 2011 to shape the future of clinical genomics. With the adoption of digital technologies, such as Next-Generation DNA Sequencing (NGS), the industry entered the Big Data world raising new challenges in data analysis and security. To solve these challenges a team of world renowned experts have developed SOPHiA Artificial Intelligence (AI). Like Swiss watchmakers, SOPHiA GENETICS’ technology is recognized for its quality, accuracy and reliability. Resulting in both ISO 13485 (Medical Devices Quality Management) and ISO 27001 (Information Security Management) accreditations.
SOPHiA AI is a universal technology which is used today by hundreds of healthcare institutions worldwide contributing to SOPHiA GENETICS’ rapidly expanding genomics community.
Adrienne Corboud Fumagalli, Vice President for Innovation and Technology Transfer at EPFL: "SOPHiA GENETICS is a Swiss success story, and at EPFL we are proud of its evolution from start-up launched in our Innovation Park, to established European market leader in genomic analysis."
SOPHiA GENETICS provides an advanced and universal technology for NGS data analysis. We offer tailored solutions to meet your lab’s specific needs:
SOPHiA, the collective Artificial Intelligence for Data-Driven Medicine, (exclusively available on SOPHiA DDM) detects, annotates and pre-classifies genomic variants, to help clinicians make use of them so that they can better diagnose and treat their patients.
SOPHiA DDM is a software-as-a-service platform that facilitate variants visualization and interpretation, thanks to its intuitive user interface and integrated features. Moreover, it assures protection of all the data by encrypting them to the highest industry standards before storing it redundantly in secured and private data centers.
It enables analysis and protection of clinical NGS data. Our core technologies process and analyse raw genomic data to help hospitals accurately and speedily diagnose patients in areas including oncology, metabolism, pediatrics, cardiology and hereditary cancer.
SOPHiA GENETICS has gathered hundreds of healthcare institutions participating in the democratization of Data-Driven Medicine. Through SOPHiA DDM, experts from hundreds of institutions can easily interpret the variants and flag them with the appropriate level of pathogenicity. This highly valuable information feeds the variant knowledge base and is anonymously and safely shared among the members of the community. Thus enabling clinicians around the world to collaborate, and find better treatment options for their patients.